The Union health ministry has proposed amending the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under the definition of "new drug," a change that would require manufacturers to obtain permission from the Central Licensing Authority before applying to a state licensing authority for a manufacturing licence. The draft notification, G.S.R. 983(E) dated November 6, was announced in a ministry statement on Thursday.

According to the statement, the move is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products. At present, state licensing authorities grant manufacturing licences for these products, and the amendment was prompted by concerns that some were cleared without adequate regulatory scrutiny, including studies such as bioavailability/bioequivalence and stability studies, according to persons aware of the matter. The ministry said substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety.

A senior health ministry official, who asked not to be named, said the change will apply prospectively. Licences already granted will remain valid, and existing licence holders will not have to reapply. The official described the proposal as an additional regulatory safeguard against antimicrobial resistance by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before new manufacturing licences are granted, and as part of broader efforts to promote responsible use of antimicrobials and safeguard patient safety.

Antimicrobial resistance is a major global public health concern requiring coordinated action, and the G20 New Delhi Leaders' Declaration underscored the need to address it through a One Health approach. The draft has been issued to invite objections and suggestions from stakeholders and the public within 30 days before the central government considers it for finalisation.